Boehringer gets EU approval for new antihypertensive drug strength

TriMed Staff | | Health Imaging | Screening

The European Commission has granted marketing authorization to Boehringer Ingelheim for a new strength of its fixed dose combination antihypertensive drug MicardisPlus 80/25 in all 27 EU member states.

The drug will be launched in Germany and Denmark in the coming weeks, followed soon by Ireland, the United Kingdom and the rest of the EU, according to the Ingelheim, Germany-based company.

The product is licensed for the treatment of hypertension in patients whose blood pressure is not adequately controlled on MicardisPlus 80/12.5 (80 mg telmisartan/12.5 mg hydrochlorothiazide) or patients, who have been previously stabilized on telmisartan and hydrochlorothiazide separately at the same dosages, the company said.

The new strength will be marketed by Boehringer in the 27 countries of the EU under the brand name MicardisPlus 80/25, and the company’s co-marketing partners will market the new drug in selected countries under its own brands. 

TriMed Staff

Related Content

AI reduces CT lung cancer screening workload by nearly 80%
Abbreviated MRI protocols present suitable alternatives for liver cancer screening
Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans

Around the web

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care. 

Cardiovascular Business
Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.